Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study

Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing–remitting multiple sclerosis. This post hoc analysis of the Phase III TOWER study evaluated the effects of teriflunomide treatment on five severe relapse outcomes: relapses with sequelae defined by an increase...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Miller, Aaron E., Macdonell, Richard, Comi, Giancarlo, Freedman, Mark S., Kappos, Ludwig, Mäurer, Mathias, Olsson, Tomas P., Wolinsky, Jerry S., Bozzi, Sylvie, Dive-Pouletty, Catherine, O’Connor, Paul W.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2014
Témata:
Original Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4155167/
https://ncbi.nlm.nih.gov/pubmed/24972678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-014-7395-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky